Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions-Reference-Cited by-同舟云学术

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Published:2018-02-26 Issue:5 Volume:17 Page:885-896
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Floc'h Nicolas,Martin Matthew J.,Riess Jonathan W.,Orme Jonathan P.,Staniszewska Anna D.,Ménard Ludovic,Cuomo Maria Emanuela,O'Neill Daniel J.,Ward Richard A.,Finlay M. Raymond V.,McKerrecher Darren,Cheng Mingshan,Vang Daniel P.,Burich Rebekah A.,Keck James G.,Gandara David R.,Mack Philip C.,Cross Darren A.E.

Funder

National Institutes of Health

NCI

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19);Lung Cancer;2024-08

2. A Review: CRISPR Cas System and the Mechanism With an Inhibition of Binding of CRISPR Cas‐9;Nano Select;2024-07-18

3. CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders;Cell Communication and Signaling;2024-06-14

4. The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation;Frontiers in Oncology;2024-06-11

5. Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO);ESMO Open;2024-06